Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Photo/Multimedia, Award

Fierce Biotech Names Amylyx Pharmaceuticals as One of Its "Fierce 15" Biotech Companies of 2020

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases, today announced that it has been named by Fierce Biotech as one of 2020's Fierce 15 biotechnology companies, designating Amylyx as one of the most promising private biotechnology companies in the industry.

The 2020 Fierce 15 comes at a time when the world is focused on a pandemic, but even as coronavirus remains a threat, patients with cancer, rare diseases and other disorders still need treatment, Fierce Biotech Senior Editor Ben Adams said. "This year, we've chosen from a diverse range of those fighting COVID, as well as those fighting longer term plagues against our biology," Adams said.

Amylyx' lead product candidate, AMX0035, is an investigational neuroprotective therapy that seeks to prevent or reduce neuron death and dysfunction in ALS and other neurodegenerative diseases. Recently, Amylyx announced positive results from the pivotal CENTAUR trial evaluating AMX0035 in people with ALS, published in the New England Journal of Medicine. Amylyx continues to evaluate the long-term effects of AMX0035 in people with ALS in an ongoing open-label extension (OLE) of CENTAUR, and plans to publish the results from this study in Q4 2020. Additionally, AMX0035 is being evaluated for Alzheimer's disease in the Phase 2 PEGASUS trial and expects topline results in Q1 2021.

"Amylyx is honored to be named one of Fierce Biotech's Fierce 15 of 2020. This recognition highlights the tremendous responsibility our team has to continue working towards bringing a new potential treatment to those living with neurodegenerative diseases," said Justin Klee, Co-CEO and Co-Founder of Amylyx.

An internationally recognized daily report reaching a network of over 285,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day's top stories. Every year Fierce Biotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About Fierce Biotech

Fierce Biotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.

These press releases may also interest you

at 18:05
The yeast market is poised to grow by USD 7.06 billion during 2020-2024 progressing at a CAGR of over 9% during the forecast period. The report on the yeast market provides a holistic update, market size and forecast, trends, growth drivers, and...

at 18:01
Zurich North America Insurance and Advisen Ltd. has released the tenth annual Advisen cyber survey of corporate risk managers and insurance buyers revealing current views about information security and cyber risk management. This year's survey...

at 18:00
Steel Dynamics, Inc. today announced third quarter 2020 financial results. The company reported third quarter 2020 net sales of $2.3 billion and net income of $100 million, or $0.47 per diluted share. Excluding the impact from the following item,...

at 18:00
F.N.B. Corporation reported earnings for the third quarter of 2020 with net income available to common stockholders of $80.8 million, or $0.25 per diluted common share. Comparatively, third quarter of 2019 net income available to common stockholders...

at 18:00
By its very nature, technology requires industry players to innovate in order to survive. In fact, technology companies are 12 percent more likely to be disrupted than companies in retail and 25 percent more likely than those in financial services,...

at 18:00
More than 50, 000 people from across the country are expected to take part in Light The Night, Take Back The Light ? an annual flagship event hosted by The Leukemia & Lymphoma Society of Canada (LLSC). For the first time in the organization's...

News published on 28 september 2020 at 12:25 and distributed by: